RARE CANCERUnknown PrimaryWHO 5th Edition Classification

Cancer of Unknown Primary (CUP)

Rare Malignancy (< 6 cases per 100,000 / year) • Clinical Staging, Genomic Targets & Vetted Specialists

A metastatic cancer for which no primary site can be identified after a standard diagnostic work-up. It is a working diagnosis, not a single disease. The essential clinical task is to identify the favourable subsets - which are treated as if the primary were known, often with good outcomes - and to distinguish them from the unfavourable majority.

Request Rare Cancer Tumor Board Find NCI Treatment CentersAsk Vani AI Navigator

Emergent Referral AdvisoryImmediate Action

Certain rare malignancies progress rapidly or carry acute risk of airway obstruction, acute spinal compression, hydrocephalus, or biopsy-seeding. Do not perform needle biopsy or surgery outside of an NCI-designated specialty sarcoma or neuro-oncology unit without multidisciplinary tumor board review.

Report immediately to an emergency department or tertiary oncologist upon:

  • Always search actively for a favourable subset before defaulting to empirical chemotherapy
Who It Affects

Adults, median 60-70; incidence falling as imaging and pathology improve

Annual Incidence

Approximately 2-5% of all cancer diagnoses, and declining

Clinical Evidence Review

Last audited: 2026-08-13 against NCCN, ESMO, and WHO 5th ed. guidelines.

Clinical Presentation & Hallmark Symptoms

Presenting signs most frequently observed across clinical case series

Enlarged lymph nodes without an obvious source
Unexplained weight loss and fatigue
Pain at the site of metastases, commonly bone or liver
Abdominal swelling from ascites
Breathlessness from lung or pleural involvement

Genomic Profiling & Defining Molecular Lesions

Critical diagnostic fusions, somatic mutations, and therapeutic targets

Rare malignancies frequently depend on distinct oncogenic drivers rather than conventional environmental carcinogens. Comprehensive Next-Generation Sequencing (NGS comprehensive panel) and FISH/IHC are mandatory to establish the true diagnosis and screen for basket trial agents.

IHC panel - CK7/CK20, TTF-1, GATA3, CDX2, PAX8, p40MSI-H / dMMRTumour mutational burdenActionable fusions - NTRK, ALK, RET

Standard-of-Care Treatment Protocol

Frontline and multimodal strategies established under international consensus guidelines

1

A structured immunohistochemistry algorithm to assign likely tissue of origin

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

2

Comprehensive genomic profiling and, where available, tissue-of-origin molecular classifiers

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

3

Site-specific treatment for favourable subsets - for example, treating isolated axillary nodal adenocarcinoma in a woman as breast cancer

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

4

Platinum-based combination chemotherapy for unfavourable subsets

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

5

Immunotherapy where MSI-H, high tumour mutational burden or high PD-L1 is present

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

6

Targeted therapy against any actionable alteration found, regardless of presumed origin

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

Clinical Trial Advisory: For rare and ultra-rare malignancies, enrollment in an active clinical trial or expanded-access program is widely considered the preferred standard of care by ASCO and NCCN panels.

Prognosis & Disease Trajectory

Objective clinical outlook without false reassurance

Highly variable and driven entirely by subset. Favourable subsets - including isolated axillary nodal adenocarcinoma in women, squamous carcinoma in cervical nodes, peritoneal serous carcinoma, and single resectable metastases - can achieve outcomes comparable to the equivalent known primary. The unfavourable majority has median survival of approximately 6-12 months.

Note: Statistics reflect cohort averages. Individual outcomes depend heavily on performance status, resectability, biomarker expression, and timely access to specialized tertiary care.

Active Research, Biomarkers & Clinical Trials

Novel investigational agents, phase I/II trials, and international rare disease consortia

Molecular tissue-of-origin classifiers and site-specific therapy directed by them have been tested in randomised trials with mixed results; the clearer benefit so far has come from acting on actionable alterations and immunotherapy biomarkers rather than from predicted site alone.

Need Help Matching to an Active Rare Cancer Trial?

ByOnco scans ClinicalTrials.gov, NCI trial networks, and institutional registries for open patient cohorts.

Request Trial Match
Expert Clinicians

Verified Specialists for Cancer of Unknown Primary

Browse All Oncologists

Dr. Anthony Greco

Medical Oncologist

45+ yrs exp

Sarah Cannon Research Institute

Nashville, USA

Medical OncologyCUPEmpiric Chemotherapy
Vetted DirectoryConsult Specialist

Dr. Ravindran Kanesvaran

Medical Oncologist

15+ yrs exp

NCCS

Singapore, Singapore

Medical OncologyCUP ServiceMolecular Profiling
Vetted DirectoryConsult Specialist

Prof. Fizazi Karim

Medical Oncologist

20+ yrs exp

Gustave Roussy

Villejuif, France

Medical OncologyCUP TrialsESMO Guidelines
Vetted DirectoryConsult Specialist

Dr. Harit Chaturvedi

Surgical Oncologist

30+ yrs exp

Max Healthcare

Delhi, India

Surgical OncologyCUPTreatable Subsets
Vetted DirectoryConsult Specialist
Hospital Network

Designated Cancer Centers with Dedicated Programs

Search All 72 NCI Centers

Memorial Sloan Kettering Cancer Center

NY

NCI-Designated Comprehensive Cancer Center

World-leading rare tumor board & pediatric solid tumor protocols

Proton TherapyCAR-T Cell TherapyRobotic Surgery
1,000+ Active Clinical TrialsView Center Profile

University of Texas MD Anderson Cancer Center

TX

NCI-Designated Comprehensive Cancer Center

Largest specialized rare cancer and sarcoma multidisciplinary program

Proton TherapyCAR-T Cell TherapyCyberKnife SBRT
1,200+ Active Clinical TrialsView Center Profile

Dana-Farber / Harvard Cancer Center

MA

NCI-Designated Comprehensive Cancer Center

Pioneering genomic molecular tumor boards & rare histologies

Proton TherapyCAR-T Cell TherapyPhase I Unit
1,100+ Active Clinical TrialsView Center Profile

Mayo Clinic Comprehensive Cancer Center

MN

NCI-Designated Comprehensive Cancer Center

High-volume surgical oncology & rare endocrine/neuroendocrine expertise

Proton TherapyCAR-T Cell TherapyCyberKnife SBRT
600+ Active Clinical TrialsView Center Profile

Frequently Asked Clinical Questions

Authoritative guidance on diagnosis, tumor boards, genomic markers, and care options

Related Rare Malignancies in Catalog

rare

Malignant Mesothelioma

rare

Retinoblastoma

rare

Ewing Sarcoma

rare

Osteosarcoma

Independent Tumor Board Review

Facing a Diagnosis of Cancer of Unknown Primary?

Rare cancers demand rare expertise. Connect your medical records to US NCI-fellowship trained oncologists, subspecialist pathologists, and active clinical trial investigators within 12 to 72 hours.

Upload Scans for Second Opinion Schedule Virtual Teleconsult